Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

• Status: Completed
• Trial end date: 2017-03-01

Summary

The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.

• Phase: N/A

Details

• Lead Sponsor: EPS Corporation
• Treatments: Bevacizumab; Cetuximab; Fluorouracil; Liver Extracts; Oxaliplatin